Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.

Harrison C, Kiladjian JJ, Vannucchi AM, Mesa RA

Open source

DOI
10.1080/14796694.2024.2440255
Published
2025 Mar
Container
Future oncology (London, England)
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2024.2440255,
  title = {Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.},
  author = {Harrison C and Kiladjian JJ and Vannucchi AM and Mesa RA},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2024.2440255},
  url = {https://doi.org/10.1080/14796694.2024.2440255}
}

RIS

TY  - JOUR
TI  - Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.
AU  - Harrison C
AU  - Kiladjian JJ
AU  - Vannucchi AM
AU  - Mesa RA
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2024.2440255
UR  - https://doi.org/10.1080/14796694.2024.2440255
ER  - 

APA

C, H., JJ, K., AM, V., & RA, M. (2025). Earlier versus delayed ruxolitinib treatment for patients with myelofibrosis: a plain language summary.. Future oncology (London, England). https://doi.org/10.1080/14796694.2024.2440255

Source records